| Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. | |
| | |
MedLine Citation:
|
PMID: 6298567 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Parathyroid function and calcium metabolism were studied in 44 patients under glucocorticoid therapy (steroid group) and in 25 control subjects. Nephrogenous cAMP and serum immunoreactive parathyroid hormone levels in the steroid group were significantly higher than those in control subjects (p less than 0.001). Nephrogenous cAMP in the steroid group correlated positively with prednisolone dosage (r = 0.424, p less than 0.01), and most patients who showed obvious elevations of nephrogenous cAMP had received over 10 mg/day of prednisolone for at least 2 mo. Fasting urinary calcium in the steroid group [166.1 +/- 78.5 (+/- SD) mg/g creatinine] was about 2 times greater than that in control subjects (74.1 +/- 35.6) (p less than 0.001). Fasting urinary calcium in control subjects correlated negatively with nephrogenous cAMP (r = -0.486, p less than 0.02). In contrast, these values in steroid group showed significant positive correlation (r = 0.631, p less than 0.001), suggesting that increased urinary calcium excretion is an important factor in the development of secondary hyperparathyroidism. Elevated nephrogenous cAMP and serum immunoreactive parathyroid hormone levels decreased after the administration of trichlormethiazide and/or 1 alpha hydroxy-vitamin D3. We conclude that increased urinary calcium excretion plays an important role in the development of secondary hyperparathyroidism in patients under glucocorticoid therapy and that the administration of thiazide and/or vitamin D could improve the secondary hyperparathyroidism caused by glucocorticoid therapy. |
| | |
Authors:
|
Y Suzuki; Y Ichikawa; E Saito; M Homma |
Related Documents
:
|
2203847 - Calcium supplementation lowers serum parathyroid hormone levels in elderly subjects. 1133897 - Role of parathyroid hormone in the phosphaturia of extracellular fluid volume expansion. 7771507 - Neutral phosphate administration generates and maintains renal metabolic alkalosis and ... 10977787 - Intermittent doxercalciferol (1alpha-hydroxyvitamin d(2)) therapy for secondary hyperpa... 1653207 - Effect of exogenous camp and aminophylline on alveolar and lung liquid clearance in ane... 1364937 - Morning stiffness and nightime pain in ankylosing spondylitis. a comparison between ent... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Metabolism: clinical and experimental Volume: 32 ISSN: 0026-0495 ISO Abbreviation: Metab. Clin. Exp. Publication Date: 1983 Feb |
Date Detail:
|
Created Date: 1983-04-07 Completed Date: 1983-04-07 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0375267 Medline TA: Metabolism Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 151-6 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Calcium / urine* Cyclic AMP / metabolism Fasting Female Glucocorticoids / adverse effects* Humans Hydroxycholecalciferols / therapeutic use Hyperparathyroidism, Secondary / chemically induced*, drug therapy Kidney / metabolism Male Middle Aged Trichlormethiazide / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Glucocorticoids; 0/Hydroxycholecalciferols; 133-67-5/Trichlormethiazide; 41294-56-8/1-hydroxycholecalciferol; 60-92-4/Cyclic AMP; 7440-70-2/Calcium |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Evidence for thyroid hormone receptors in uterine nuclei.
Next Document: Discrimination of multiple forms of phosphoprotein phosphatase in bovine thyroid.